Skip to main content
Erschienen in: Drugs 10/2013

01.07.2013 | Adis Drug Evaluation

Abatacept: A Review of its Use in the Management of Rheumatoid Arthritis

verfasst von: Gillian M. Keating

Erschienen in: Drugs | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

The biological disease-modifying antirheumatic drug abatacept (Orencia®) has a novel mechanism of action; its activity is mediated via the selective modulation of T cell co-stimulation. This article reviews the clinical efficacy and tolerability of intravenous and subcutaneous abatacept in patients with rheumatoid arthritis (RA) and intravenous abatacept in patients with juvenile idiopathic arthritis (JIA), as well as summarizing its pharmacological properties. In patients with RA, the beneficial effects of intravenous or subcutaneous abatacept on signs and symptoms, disease activity, the progression of structural damage, physical function and/or health-related quality of life were seen in a number of well-designed trials, including in methotrexate-naive patients with early RA and poor prognostic factors and in patients with established RA and an inadequate response to either methotrexate or anti-tumour necrosis factor therapy. Subcutaneous abatacept plus methotrexate was also noninferior to subcutaneous adalimumab plus methotrexate in patients with active RA who were naive to biological therapy and had an inadequate response to methotrexate. In paediatric patients with JIA, intravenous abatacept improved signs and symptoms and delayed the time to flare. Abatacept was generally well tolerated in RA and JIA and was associated with low rates of immunogenicity. In conclusion, abatacept is an important option for use in the treatment of RA and JIA.
Literatur
1.
Zurück zum Zitat Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559–82.PubMedCrossRef Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559–82.PubMedCrossRef
2.
Zurück zum Zitat Levesque MC. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data? BioDrugs. 2012;26(2):65–70.PubMedCrossRef Levesque MC. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data? BioDrugs. 2012;26(2):65–70.PubMedCrossRef
3.
Zurück zum Zitat Goldzweig O, Hashkes PJ. Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des Devel Ther. 2011;5:61–70.PubMed Goldzweig O, Hashkes PJ. Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des Devel Ther. 2011;5:61–70.PubMed
4.
Zurück zum Zitat Kuemmerle-Deschner JB, Benseler S. Abatacept in difficult-to-treat juvenile idiopathic arthritis. Biologics. 2008;2(4):865–74.PubMed Kuemmerle-Deschner JB, Benseler S. Abatacept in difficult-to-treat juvenile idiopathic arthritis. Biologics. 2008;2(4):865–74.PubMed
5.
Zurück zum Zitat Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82.CrossRef Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82.CrossRef
6.
Zurück zum Zitat Teng GG, Turkiewicz AM, Moreland LW. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2005;5(9):1245–54.PubMedCrossRef Teng GG, Turkiewicz AM, Moreland LW. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2005;5(9):1245–54.PubMedCrossRef
7.
Zurück zum Zitat Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006;24(3):233–8.PubMedCrossRef Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006;24(3):233–8.PubMedCrossRef
8.
Zurück zum Zitat Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–39.CrossRef Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–39.CrossRef
9.
Zurück zum Zitat Corbo M, Valencia X, Raymond R, et al. Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity [abstract no. SAT0101]. Ann Rheum Dis. 2009;68(Suppl. 3):574. Corbo M, Valencia X, Raymond R, et al. Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity [abstract no. SAT0101]. Ann Rheum Dis. 2009;68(Suppl. 3):574.
10.
Zurück zum Zitat Nadler S, Townsend R, Mikesell G, et al. Abatacept (CTLA4g; BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrations [abstract no. THU0103]. Ann Rheum Dis. 2004;63:142–3. Nadler S, Townsend R, Mikesell G, et al. Abatacept (CTLA4g; BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrations [abstract no. THU0103]. Ann Rheum Dis. 2004;63:142–3.
11.
Zurück zum Zitat Davis PM, Nadler SG, Rouleau KA, et al. Abatacept (CTLA4-Ig) modulates human T-cell proliferation and cytokine production but does not affect lipopolysaccharide-induced tumor necrosis factor alpha production by monocytes [abstract]. Arthritis Res Ther. 2005;7(Suppl. 1):P21.CrossRef Davis PM, Nadler SG, Rouleau KA, et al. Abatacept (CTLA4-Ig) modulates human T-cell proliferation and cytokine production but does not affect lipopolysaccharide-induced tumor necrosis factor alpha production by monocytes [abstract]. Arthritis Res Ther. 2005;7(Suppl. 1):P21.CrossRef
12.
Zurück zum Zitat Cutolo ME, Soldano S, Montagna P, et al. CTLA-4-Ig fusion protein (abatacept) modulate inflammatory activity of cultured synovial macrophages from rheumatoid arthritis patients [abstract no. 1798]. American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting; 7–11 Nov 2010; Atlanta (GA). Cutolo ME, Soldano S, Montagna P, et al. CTLA-4-Ig fusion protein (abatacept) modulate inflammatory activity of cultured synovial macrophages from rheumatoid arthritis patients [abstract no. 1798]. American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting; 7–11 Nov 2010; Atlanta (GA).
13.
Zurück zum Zitat Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009;104(4):276–84.PubMedCrossRef Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009;104(4):276–84.PubMedCrossRef
14.
Zurück zum Zitat Ruderman EM, Pope RM. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther. 2005;7(Suppl. 2):S21–5.PubMedCrossRef Ruderman EM, Pope RM. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther. 2005;7(Suppl. 2):S21–5.PubMedCrossRef
15.
Zurück zum Zitat von Kempis J, Dudler J, Hasler P, et al. Use of abatacept in rheumatoid arthritis: recommendations based on current evidence. Swiss Med Wkly. 2012;142:w13581. von Kempis J, Dudler J, Hasler P, et al. Use of abatacept in rheumatoid arthritis: recommendations based on current evidence. Swiss Med Wkly. 2012;142:w13581.
16.
Zurück zum Zitat Platt AM, Gibson VB, Patakas A, et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol. 2010;185(3):1558–67.PubMedCrossRef Platt AM, Gibson VB, Patakas A, et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol. 2010;185(3):1558–67.PubMedCrossRef
17.
Zurück zum Zitat Davis PM, Abraham R, Xu L, et al. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol. 2007;34(11):2204–10.PubMed Davis PM, Abraham R, Xu L, et al. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol. 2007;34(11):2204–10.PubMed
18.
Zurück zum Zitat Roy A, Mould DR, Wang X-F, et al. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol. 2007;47(11):1408–20.PubMedCrossRef Roy A, Mould DR, Wang X-F, et al. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol. 2007;47(11):1408–20.PubMedCrossRef
19.
Zurück zum Zitat Davis PM, Nadler SG, Stetsko DK, et al. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol. 2008;126(1):38–47.PubMedCrossRef Davis PM, Nadler SG, Stetsko DK, et al. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol. 2008;126(1):38–47.PubMedCrossRef
20.
Zurück zum Zitat Scarsi M, Ziglioli T, Airo P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol. 2010;37(5):911–6.PubMedCrossRef Scarsi M, Ziglioli T, Airo P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol. 2010;37(5):911–6.PubMedCrossRef
21.
Zurück zum Zitat Bonelli M, Ferner E, Göschl L, et al. Abatacept (CTLA-4Ig) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65(3):599–607.PubMedCrossRef Bonelli M, Ferner E, Göschl L, et al. Abatacept (CTLA-4Ig) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65(3):599–607.PubMedCrossRef
22.
Zurück zum Zitat Weisman MH, Durez P, Hallegua D, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006;33(11):2162–6.PubMed Weisman MH, Durez P, Hallegua D, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006;33(11):2162–6.PubMed
23.
Zurück zum Zitat Matsubara T, Yamana S, Tohma S, et al. Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. Mod Rheumatol. 2012. doi:10.1007/s10165-012-0722-x. Matsubara T, Yamana S, Tohma S, et al. Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. Mod Rheumatol. 2012. doi:10.​1007/​s10165-012-0722-x.
24.
Zurück zum Zitat Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis. 2009;68(7):1220–7.PubMedCrossRef Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis. 2009;68(7):1220–7.PubMedCrossRef
25.
Zurück zum Zitat Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(8):2263–71.PubMedCrossRef Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(8):2263–71.PubMedCrossRef
26.
Zurück zum Zitat Murthy B, Gao L, Yin J, et al. Pharmacokinetics of subcutaneous abatacept support a fixed dosing regimen in adult patients with rheumatoid arthritis [abstract no. FRI0347]. Ann Rheum Dis. 2011;70(Suppl. 3):460. Murthy B, Gao L, Yin J, et al. Pharmacokinetics of subcutaneous abatacept support a fixed dosing regimen in adult patients with rheumatoid arthritis [abstract no. FRI0347]. Ann Rheum Dis. 2011;70(Suppl. 3):460.
27.
Zurück zum Zitat Murthy B, Gao L, Vakkalagadda B, et al. Clinical pharmacokinetics of subcutaneous abatacept in the presence or absence of an intravenous loading dose in patients with rheumatoid arthritis [abstract no. FRI0346]. Ann Rheum Dis. 2011;70(Suppl. 3):459. Murthy B, Gao L, Vakkalagadda B, et al. Clinical pharmacokinetics of subcutaneous abatacept in the presence or absence of an intravenous loading dose in patients with rheumatoid arthritis [abstract no. FRI0346]. Ann Rheum Dis. 2011;70(Suppl. 3):459.
30.
Zurück zum Zitat Hasegawa M, Imai Y, Hiraoka M, et al. Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn. 2011;38(6):803–32.PubMedCrossRef Hasegawa M, Imai Y, Hiraoka M, et al. Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn. 2011;38(6):803–32.PubMedCrossRef
31.
Zurück zum Zitat Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46(6):1470–9.PubMedCrossRef Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46(6):1470–9.PubMedCrossRef
32.
Zurück zum Zitat Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349(20):1907–15.PubMedCrossRef Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349(20):1907–15.PubMedCrossRef
33.
Zurück zum Zitat Takeuchi T, Matsubara T, Nitobe T, et al. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol. 2013;23(2):226–35.PubMedCrossRef Takeuchi T, Matsubara T, Nitobe T, et al. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol. 2013;23(2):226–35.PubMedCrossRef
34.
Zurück zum Zitat Westhovens R, Kremer JM, Moreland LW, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009;36(4):736–42.PubMedCrossRef Westhovens R, Kremer JM, Moreland LW, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009;36(4):736–42.PubMedCrossRef
35.
Zurück zum Zitat Westhovens R, Kremer JM, Emery P, et al. Consistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologic-naive patients with RA [abstract no. SAT0108]. Ann Rheum Dis. 2009;68(Suppl. 3):577. Westhovens R, Kremer JM, Emery P, et al. Consistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologic-naive patients with RA [abstract no. SAT0108]. Ann Rheum Dis. 2009;68(Suppl. 3):577.
36.
Zurück zum Zitat Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865–76.PubMedCrossRef Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865–76.PubMedCrossRef
37.
Zurück zum Zitat Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096–103.PubMedCrossRef Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096–103.PubMedCrossRef
38.
Zurück zum Zitat Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis. 2012. doi:10.1136/annrheumdis-2012-201611. Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis. 2012. doi:10.​1136/​annrheumdis-2012-201611.
39.
Zurück zum Zitat Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med. 2005;353(11):1114–23.PubMedCrossRef Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med. 2005;353(11):1114–23.PubMedCrossRef
40.
Zurück zum Zitat Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870–7.PubMedCrossRef Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870–7.PubMedCrossRef
41.
Zurück zum Zitat Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708–14.PubMedCrossRef Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708–14.PubMedCrossRef
42.
Zurück zum Zitat Nüβlein H, Alten R, Galeazzi M, et al. Real-world efficacy and safety of abatacept treatment for RA: 12-month interim analysis of the ACTION study [abstract no. AB0531]. Ann Rheum Dis. 2012;71(Suppl. 3):668. Nüβlein H, Alten R, Galeazzi M, et al. Real-world efficacy and safety of abatacept treatment for RA: 12-month interim analysis of the ACTION study [abstract no. AB0531]. Ann Rheum Dis. 2012;71(Suppl. 3):668.
43.
Zurück zum Zitat Nüβlein H, Alten R, Galeazzi M, et al. Effect of prior therapy on the efficacy and safety of abatacept: 6-month analysis of the ACTION study [abstract no. AB0532]. Ann Rheum Dis. 2012;71(Suppl. 3):668. Nüβlein H, Alten R, Galeazzi M, et al. Effect of prior therapy on the efficacy and safety of abatacept: 6-month analysis of the ACTION study [abstract no. AB0532]. Ann Rheum Dis. 2012;71(Suppl. 3):668.
44.
Zurück zum Zitat Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann Rheum Dis. 2012;71(11):1815–9.PubMedCrossRef Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann Rheum Dis. 2012;71(11):1815–9.PubMedCrossRef
45.
Zurück zum Zitat Genant HK, Peterfy C, Westhovens R, et al. Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RA [abstract no. FRI0253]. Ann Rheum Dis. 2009;68(Suppl. 3):440. Genant HK, Peterfy C, Westhovens R, et al. Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RA [abstract no. FRI0253]. Ann Rheum Dis. 2009;68(Suppl. 3):440.
46.
Zurück zum Zitat Durez P, Bathon J, Becker JC, et al. Time course of improvement in ACR core components in patients with early rheumatoid arthritis (RA) treated with abatacept (ABA) + methotrexate (MTX) [abstract no. FRI0201]. Ann Rheum Dis. 2010;69(Suppl. 3):382. Durez P, Bathon J, Becker JC, et al. Time course of improvement in ACR core components in patients with early rheumatoid arthritis (RA) treated with abatacept (ABA) + methotrexate (MTX) [abstract no. FRI0201]. Ann Rheum Dis. 2010;69(Suppl. 3):382.
47.
Zurück zum Zitat Westhovens R, Dougados M, Hall S, et al. Disease remission, radiographic non-progression and normalization of function achieved at year 1 are sustained long-term in a majority of patients: 5-year outcomes with abatacept in biologic-naive patients [abstract no. 1657]. 2009 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting; 16–21 Oct 2009; Philadelphia (PA). Westhovens R, Dougados M, Hall S, et al. Disease remission, radiographic non-progression and normalization of function achieved at year 1 are sustained long-term in a majority of patients: 5-year outcomes with abatacept in biologic-naive patients [abstract no. 1657]. 2009 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting; 16–21 Oct 2009; Philadelphia (PA).
48.
Zurück zum Zitat Bathon J, Robles M, Ximenes AC, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis. 2011;70(11):1949–56.PubMedCrossRef Bathon J, Robles M, Ximenes AC, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis. 2011;70(11):1949–56.PubMedCrossRef
49.
Zurück zum Zitat Wells AF, Westhovens R, Reed DM, et al. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol. 2011;38(11):2362–8.PubMedCrossRef Wells AF, Westhovens R, Reed DM, et al. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol. 2011;38(11):2362–8.PubMedCrossRef
50.
Zurück zum Zitat Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008;58(4):953–63.PubMedCrossRef Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008;58(4):953–63.PubMedCrossRef
51.
Zurück zum Zitat Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis. 2008;67(8):1084–9.PubMedCrossRef Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis. 2008;67(8):1084–9.PubMedCrossRef
52.
Zurück zum Zitat Kremer JM, Russell AS, Emery P, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70(10):1826–30.PubMedCrossRef Kremer JM, Russell AS, Emery P, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70(10):1826–30.PubMedCrossRef
53.
Zurück zum Zitat Schiff M, Keiserman M, Codding C, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis. 2011;70(11):2003–7.PubMedCrossRef Schiff M, Keiserman M, Codding C, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis. 2011;70(11):2003–7.PubMedCrossRef
54.
Zurück zum Zitat Russell AS, Wallenstein GV, Li T, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis. 2007;66(2):189–94.PubMedCrossRef Russell AS, Wallenstein GV, Li T, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis. 2007;66(2):189–94.PubMedCrossRef
55.
Zurück zum Zitat Wells G, Li T, Tugwell P. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. Ann Rheum Dis. 2010;69(10):1768–73.PubMedCrossRef Wells G, Li T, Tugwell P. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. Ann Rheum Dis. 2010;69(10):1768–73.PubMedCrossRef
56.
Zurück zum Zitat Li T, Gignac M, Wells G, et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clin Ther. 2008;30(4):734–48.PubMedCrossRef Li T, Gignac M, Wells G, et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clin Ther. 2008;30(4):734–48.PubMedCrossRef
57.
Zurück zum Zitat Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67(4):547–54.PubMedCrossRef Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67(4):547–54.PubMedCrossRef
58.
Zurück zum Zitat Genovese MC, Schiff M, Luggen M, et al. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol. 2012;39(8):1546–54.PubMedCrossRef Genovese MC, Schiff M, Luggen M, et al. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol. 2012;39(8):1546–54.PubMedCrossRef
59.
Zurück zum Zitat Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford). 2006;45(10):1238–46.CrossRef Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford). 2006;45(10):1238–46.CrossRef
60.
Zurück zum Zitat Li T, Wells G, Westhovens R, et al. Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. Value Health. 2011;14(2):361–70.PubMedCrossRef Li T, Wells G, Westhovens R, et al. Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. Value Health. 2011;14(2):361–70.PubMedCrossRef
61.
Zurück zum Zitat Corbo M, Valencia X, Raymond R, et al. A subcutaneous administration regimen for abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity [abstract no. 376]. Arthritis Rheum. 2008;58(Suppl. 9):S307. Corbo M, Valencia X, Raymond R, et al. A subcutaneous administration regimen for abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity [abstract no. 376]. Arthritis Rheum. 2008;58(Suppl. 9):S307.
62.
Zurück zum Zitat Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63(10):2854–64.PubMedCrossRef Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63(10):2854–64.PubMedCrossRef
63.
Zurück zum Zitat Matsubara T, Inoue H, Iwahashi M, et al. A multi-center, double-dummy, double-blind study of subcutaneous (SC) abatacept (ABA) compared with intraveneous (IV) ABA in Japanese rheumatoid arthritis patients with inadequate response to methotrexate [abstract no. THU0125]. Ann Rheum Dis. 2012;71(Suppl. 3):197. Matsubara T, Inoue H, Iwahashi M, et al. A multi-center, double-dummy, double-blind study of subcutaneous (SC) abatacept (ABA) compared with intraveneous (IV) ABA in Japanese rheumatoid arthritis patients with inadequate response to methotrexate [abstract no. THU0125]. Ann Rheum Dis. 2012;71(Suppl. 3):197.
64.
Zurück zum Zitat Keystone EC, Kremer JM, Russell A, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis. 2012;71(6):857–61.PubMedCrossRef Keystone EC, Kremer JM, Russell A, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis. 2012;71(6):857–61.PubMedCrossRef
65.
Zurück zum Zitat Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28–38.PubMedCrossRef Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28–38.PubMedCrossRef
66.
Zurück zum Zitat Kaine J, Gladstein G, Strusberg I, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis. 2012;71(1):38–44.PubMedCrossRef Kaine J, Gladstein G, Strusberg I, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis. 2012;71(1):38–44.PubMedCrossRef
67.
Zurück zum Zitat Nash P, Nayiager S, Genovese MC, et al. Immunogenicity, safety and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res. 2013;65(5):718–28.CrossRef Nash P, Nayiager S, Genovese MC, et al. Immunogenicity, safety and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res. 2013;65(5):718–28.CrossRef
68.
Zurück zum Zitat Genovese MC, Cobos AC, Leon G, et al. Subcutaneous (SC) abatacept (ABA) versus intravenous (IV) ABA in patients (pts) with rheumatoid arthritis: long-term data from the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to Methotrexate) trial [abstract no. 402]. 2011 Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals; 5–9 Nov 2011; Chicago (IL). Genovese MC, Cobos AC, Leon G, et al. Subcutaneous (SC) abatacept (ABA) versus intravenous (IV) ABA in patients (pts) with rheumatoid arthritis: long-term data from the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to Methotrexate) trial [abstract no. 402]. 2011 Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals; 5–9 Nov 2011; Chicago (IL).
69.
Zurück zum Zitat Schiff M, Weinblatt M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab on background methotrexate in RA: two year results from the AMPLE study [abstract no. OP0044]. 2013 Annual European Congress of Rheumatology; 12–15 Jun 2013; Madrid. Schiff M, Weinblatt M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab on background methotrexate in RA: two year results from the AMPLE study [abstract no. OP0044]. 2013 Annual European Congress of Rheumatology; 12–15 Jun 2013; Madrid.
70.
Zurück zum Zitat Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91.PubMedCrossRef Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91.PubMedCrossRef
71.
Zurück zum Zitat Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1792–802.PubMedCrossRef Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1792–802.PubMedCrossRef
72.
Zurück zum Zitat Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 2010;62(11):1542–51.CrossRef Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 2010;62(11):1542–51.CrossRef
73.
Zurück zum Zitat Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807–16.PubMedCrossRef Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807–16.PubMedCrossRef
74.
Zurück zum Zitat Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013. doi:10.3899/jrheum.120906. Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013. doi:10.​3899/​jrheum.​120906.
75.
Zurück zum Zitat Alten R, Kaine J, Keystone E, et al. Safety of SC abatacept in patients with RA: update from pooled clinical trial data [abstract no. AB0567]. Ann Rheum Dis. 2012;71(Suppl. 3):670. Alten R, Kaine J, Keystone E, et al. Safety of SC abatacept in patients with RA: update from pooled clinical trial data [abstract no. AB0567]. Ann Rheum Dis. 2012;71(Suppl. 3):670.
76.
Zurück zum Zitat Simon TA, Askling J, Lacaille D, et al. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther. 2010;12(2):R67.PubMedCrossRef Simon TA, Askling J, Lacaille D, et al. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther. 2010;12(2):R67.PubMedCrossRef
77.
Zurück zum Zitat Simon TA, Smitten AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis. 2009;68(12):1819–26.PubMedCrossRef Simon TA, Smitten AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis. 2009;68(12):1819–26.PubMedCrossRef
78.
Zurück zum Zitat Weinblatt ME, Genovese MC, Schiff MH, et al. Immunogenicity is low and transient with intravenous (IV) abatacept therapy: results from a large pooled analysis of 3985 patients (pts) with rheumatoid arthritis (RA) and up to 8 years’ exposure [abstract no. 2191]. 2011 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Scientific Meeting; 5–9 Nov 2011; Chicago (IL). Weinblatt ME, Genovese MC, Schiff MH, et al. Immunogenicity is low and transient with intravenous (IV) abatacept therapy: results from a large pooled analysis of 3985 patients (pts) with rheumatoid arthritis (RA) and up to 8 years’ exposure [abstract no. 2191]. 2011 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Scientific Meeting; 5–9 Nov 2011; Chicago (IL).
79.
Zurück zum Zitat Russell AS, Kremer JM, Emery P, et al. Safety and efficacy of abatacept over 4 years of treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate in the AIM trial [abstract no. 153]. J Rheumatol. 2009;36(11):2608–9. Russell AS, Kremer JM, Emery P, et al. Safety and efficacy of abatacept over 4 years of treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate in the AIM trial [abstract no. 153]. J Rheumatol. 2009;36(11):2608–9.
80.
Zurück zum Zitat Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35(3):387–93.PubMed Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35(3):387–93.PubMed
81.
Zurück zum Zitat Smitten AL, Simon TA, Hochberg MC, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.PubMedCrossRef Smitten AL, Simon TA, Hochberg MC, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.PubMedCrossRef
83.
Zurück zum Zitat Guyot P, Taylor P, Christensen R, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthrtis Res Ther. 2011;13:R204.CrossRef Guyot P, Taylor P, Christensen R, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthrtis Res Ther. 2011;13:R204.CrossRef
84.
Zurück zum Zitat Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75.PubMedCrossRef Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75.PubMedCrossRef
85.
Zurück zum Zitat Martín Mola E, Balsa A, Martínez Taboada V, et al. Abatacept use in rheumatoid arthritis: evidence review and recommendations. Reumatol Clin. 2013;9(1):5–17.PubMed Martín Mola E, Balsa A, Martínez Taboada V, et al. Abatacept use in rheumatoid arthritis: evidence review and recommendations. Reumatol Clin. 2013;9(1):5–17.PubMed
86.
Zurück zum Zitat Westhovens R, Verschueren P. The efficacy and safety of abatacept in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2(2):89–94.PubMedCrossRef Westhovens R, Verschueren P. The efficacy and safety of abatacept in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2(2):89–94.PubMedCrossRef
89.
Zurück zum Zitat Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007;66(2):228–34.PubMedCrossRef Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007;66(2):228–34.PubMedCrossRef
90.
Zurück zum Zitat Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):995–1003.PubMedCrossRef Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):995–1003.PubMedCrossRef
91.
Zurück zum Zitat Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1–278.PubMed Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1–278.PubMed
Metadaten
Titel
Abatacept: A Review of its Use in the Management of Rheumatoid Arthritis
verfasst von
Gillian M. Keating
Publikationsdatum
01.07.2013
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 10/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0080-9

Weitere Artikel der Ausgabe 10/2013

Drugs 10/2013 Zur Ausgabe